# A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases

> **NCT05742217** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 250 (estimated)

## Conditions studied

- Relapse Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05742217
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-26
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05742217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05742217, "A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05742217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*